A randomized, 29-day, dose-ranging, efficacy and safety study of daprodustat, administered three times weekly in patients with anemia on hemodialysis

A randomized, 29-day, dose-ranging, efficacy and safety study of daprodustat, administered three times weekly in patients with anemia on hemodialysis

Abstract Background Daprodustat is a hypoxia-inducible factor-prolyl hydroxylase inhibitor currently being investigated as a treatment for anemia of chronic kidney disease (CKD) in both dialysis and nondialysis patients. In clinical studies to date, daprodustat has been administered orally as a once...

Full description

Bibliographic Details
Main Authors: Christine K. Bailey, Stephen Caltabiano, Alexander R. Cobitz, Chun Huang, Kelly M. Mahar, Vickas V. Patel
Format: Article
Language:English
Published: BMC 2019-10-01
Series:BMC Nephrology
Subjects:
Anemia
Hemodialysis
Three-times weekly (TIW)
Dose response
Bayesian
Efficacy
Online Access:http://link.springer.com/article/10.1186/s12882-019-1547-z

Internet

http://link.springer.com/article/10.1186/s12882-019-1547-z

Similar Items